You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Mismatch Repair Deficient (dMMR) Solid Tumor Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Advanced Solid Tumors Trial (RO7589831)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Aug 16, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Advanced Solid Tumor, Advanced/ Metastatic Renal Cell Carcinoma (RCC), Microsatellite Iinstability-high (MSI-H) or Mismatch

Active, not recruiting
  • Advanced Solid Tumor
  • +3 more
  • TP-1454 monotherapy
  • TP-1454 combination therapy
  • Phoenix, Arizona
  • +8 more
Nov 18, 2022

Registry Study in MSI/dMMR Solid Tumors

Not yet recruiting
  • DMMR Cancer
  • +2 more
    • (no location specified)
    Aug 21, 2023

    Recurrent Endometrial Cancer, Solid Tumors Trial in Pittsburgh (pembrolizumab, Sitravatinib)

    Recruiting
    • Recurrent Endometrial Cancer
    • Solid Tumors
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Sep 12, 2022

    MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers Trial in Kashiwa (HRO761,

    Recruiting
    • MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
    • Kashiwa, Chiba, Japan
      Novartis Investigative Site
    May 2, 2023

    Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

    Active, not recruiting
    • Colorectal Cancer
    • IBI310 (anti-CTLA-4 antibody)
    • Sintilimab(anti-PD-1 antibody)
    • Beijing, China
      Beijing cancer hospital
    Sep 15, 2022

    Solid Tumor Trial in Beijing (KN035)

    Recruiting
    • Solid Tumor
    • KN035
    • Beijing, Beijing, China
      Peking University Cancer Hospital, Peking University
    Apr 5, 2022

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Locally Advanced Malignant Solid Tumor Trial in Houston (Pembrolizumab)

    Recruiting
    • Locally Advanced Malignant Solid Neoplasm
    • Pembrolizumab
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 22, 2022

    Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

    Recruiting
    • Recurrent Endometrial Adenocarcinoma
    • +8 more
    • Ipilimumab
    • Nivolumab
    • Iowa City, Iowa
    • +9 more
    Jan 27, 2023

    Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

    Active, not recruiting
    Has Results
    • Colorectal Carcinoma
    • (no location specified)
    Oct 28, 2022

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult Trial (NEO212 Oral Capsule, Ipilimumab,

    Not yet recruiting
    • Diffuse Astrocytoma, IDH-Mutant
    • +20 more
    • NEO212 Oral Capsule
    • +8 more
    • (no location specified)
    Sep 18, 2023

    Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

    Not yet recruiting
    • Colorectal Cancer Stage IV
    • +2 more
    • (no location specified)
    Jun 19, 2022

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    MSI-H Solid Malignant Tumor Trial in China (HLX10)

    Recruiting
    • MSI-H Solid Malignant Tumor
    • Hefei, Anhui, China
    • +32 more
    Oct 26, 2022

    Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

    Recruiting
    • Colorectal Cancer
    • +3 more
    • Neoadjuvant therapy with PD-L1 inhibitor
    • Guangzhou, Guangdong, China
      the Third Affiliated Hospital of Sun Yat-Sen University
    May 10, 2022

    Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

    Not yet recruiting
    • Multiple Cancer
    • Colorectal Cancer
    • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
    • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
    • (no location specified)
    Aug 20, 2023

    Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

    Not yet recruiting
    • Melanoma
    • +5 more
    • INCB 99280 with Ipilimumab
    • (no location specified)
    Jun 9, 2023

    Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

    Not yet recruiting
    • Endometrial Neoplasms
    • Endometrial Cancer
    • Seoul, Korea, Republic of
      Severance Hospital, Yonsei University Health System
    Mar 21, 2023

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    Colon Cancer, DMMR Colorectal Cancer Trial (Dostarlimab)

    Not yet recruiting
    • Colon Cancer
    • DMMR Colorectal Cancer
    • (no location specified)
    Feb 4, 2022